Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.690
0.00 (0.00%)
At close: Feb 21, 2025, 4:00 PM
2.680
-0.010 (-0.37%)
After-hours: Feb 21, 2025, 7:48 PM EST
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
563.45M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SVRA News
- 8 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 23 days ago - Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research - Business Wire
- 24 days ago - Savara Announces Participation in Upcoming Healthcare Investor Conferences - Business Wire
- 2 months ago - Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 2 months ago - Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 - Business Wire
- 3 months ago - Savara Announces Participation in Upcoming Healthcare Conferences - Business Wire
- 3 months ago - Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire